Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C34H52N18O2 |
| Molecular Weight | 744.8961 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 4 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C\C(=N/NC(N)=N)C1=CC(=CC(NC(=O)CCCCCCCCC(=O)NC2=CC(=CC(=C2)C(\C)=N\NC(N)=N)C(\C)=N\NC(N)=N)=C1)C(\C)=N\NC(N)=N
InChI
InChIKey=PWDYHMBTPGXCSN-VCBMUGGBSA-N
InChI=1S/C34H52N18O2/c1-19(45-49-31(35)36)23-13-24(20(2)46-50-32(37)38)16-27(15-23)43-29(53)11-9-7-5-6-8-10-12-30(54)44-28-17-25(21(3)47-51-33(39)40)14-26(18-28)22(4)48-52-34(41)42/h13-18H,5-12H2,1-4H3,(H,43,53)(H,44,54)(H4,35,36,49)(H4,37,38,50)(H4,39,40,51)(H4,41,42,52)/b45-19+,46-20+,47-21+,48-22+
| Molecular Formula | C34H52N18O2 |
| Molecular Weight | 744.8961 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 4 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:30:01 UTC 2023
by
admin
on
Fri Dec 15 18:30:01 UTC 2023
|
| Record UNII |
9SGW2H1K8P
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C2149
Created by
admin on Fri Dec 15 18:30:01 UTC 2023 , Edited by admin on Fri Dec 15 18:30:01 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SEMAPIMOD
Created by
admin on Fri Dec 15 18:30:01 UTC 2023 , Edited by admin on Fri Dec 15 18:30:01 UTC 2023
|
PRIMARY | |||
|
DTXSID70870333
Created by
admin on Fri Dec 15 18:30:01 UTC 2023 , Edited by admin on Fri Dec 15 18:30:01 UTC 2023
|
PRIMARY | |||
|
5745214
Created by
admin on Fri Dec 15 18:30:01 UTC 2023 , Edited by admin on Fri Dec 15 18:30:01 UTC 2023
|
PRIMARY | |||
|
100000175237
Created by
admin on Fri Dec 15 18:30:01 UTC 2023 , Edited by admin on Fri Dec 15 18:30:01 UTC 2023
|
PRIMARY | |||
|
9SGW2H1K8P
Created by
admin on Fri Dec 15 18:30:01 UTC 2023 , Edited by admin on Fri Dec 15 18:30:01 UTC 2023
|
PRIMARY | |||
|
8349
Created by
admin on Fri Dec 15 18:30:01 UTC 2023 , Edited by admin on Fri Dec 15 18:30:01 UTC 2023
|
PRIMARY | |||
|
C96535
Created by
admin on Fri Dec 15 18:30:01 UTC 2023 , Edited by admin on Fri Dec 15 18:30:01 UTC 2023
|
PRIMARY | |||
|
CHEMBL2107779
Created by
admin on Fri Dec 15 18:30:01 UTC 2023 , Edited by admin on Fri Dec 15 18:30:01 UTC 2023
|
PRIMARY | |||
|
DB12094
Created by
admin on Fri Dec 15 18:30:01 UTC 2023 , Edited by admin on Fri Dec 15 18:30:01 UTC 2023
|
PRIMARY | |||
|
352513-83-8
Created by
admin on Fri Dec 15 18:30:01 UTC 2023 , Edited by admin on Fri Dec 15 18:30:01 UTC 2023
|
PRIMARY | |||
|
C097256
Created by
admin on Fri Dec 15 18:30:01 UTC 2023 , Edited by admin on Fri Dec 15 18:30:01 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
TARGET -> AGONIST |
CNI-1493 was found to be effective for resolving of endotoxic shock in a rat model. In a clinical trial, CNI-1493 was examined as a drug for the treatment of Crohn’s disease, a disease associated with inflammation. The investigators reported no plausible effect for CNI-1493 single and 3 day dosing. However, cumulative dosing brings some positive effects to Crohn’s disease therapy.
|
||
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
